Attana AB (NGM: ATANA)

Market Cap	10.33M
Revenue (ttm)	5.15M
Net Income (ttm)	-13.73M
Shares Out	430.61M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	924,230
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0180 - 0.1930
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Attana AB

Attana AB provides biologically related information to customers in developing pharmaceutical drugs primarily in Europe and Asia. The company offers analytical biosensor which allows studies on molecular interactions between proteins, DNA, and carbohydrates, as well as interactions to cells cultured; contract research services; and attana virus analytics. It serves academic institutions, biotech companies, and pharma companies. The company has a collaboration with the Linnaeus University. Attana AB was founded in 2002 and is headquartered in St...

• Industry: Commercial Physical and Biological Research
• Founded: 2002
• Employees: 10
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ATANA

Financial Performance

In 2023, Attana AB's revenue was 6.82 million, a decrease of -47.97% compared to the previous year's 13.11 million. Losses were -13.79 million, -5.80% less than in 2022.